Skip to content
This GLP
Updated September 2026A panel hides the monthly

Näky review

The rate on each injection card is the six-month plan, not the monthly one.

The verdict

Näky's compounded semaglutide and tirzepatide cards both advertise a rate a buyer reaches only by paying for six months at once. The month-to-month figures of $185 and $295 sit inside a pricing panel that stays shut until you open it. The daily drops are the honest exception, because $145 is the only plan they have.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection · Oral
Dose pricing
Flat across doses
Injection
From $185/mo
Oral
From $145/mo
Dose published
No
Prescription
Required
Compounded
Yes — not FDA-approved
Pharmacy
Not named

Näky sells compounded semaglutide and compounded tirzepatide as weekly injections, a daily semaglutide drop taken under the tongue, and a branded oral semaglutide pill, with a separate microdosing line and a longevity line running NAD+ and sermorelin alongside them. The trading entity names itself on the product pages and states that it is not affiliated with the manufacturer whose brands it references.

  1. Who writes the prescription, and what do they see?

    A licensed provider reviews the free medical intake before anything is charged, and the site is explicit that a patient pays only if a prescription is written. Someone arriving already on a GLP-1 is asked for their current dose during intake, so the provider can continue it rather than start them over. Most sellers leave that to a support ticket after the first vial has already arrived.

    Each injection is sold as a one, three or six month plan, and the longer the plan the lower the monthly figure, with the six-month rate being the one the card advertises. The drops are sold monthly and only monthly. Shipping is free and stated as two-day, the pharmacies are described as United States based and FDA-regulated rather than named, and the trust bar running across every page promises the same price at every dose.

  2. What happens when the dose goes up?

    Näky states that the price holds at every dose, so the ladder itself costs nothing extra, and a new patient is started on a low dose to ease the first weeks. A transferring patient keeps their existing dose rather than dropping back to the bottom. What the site does not publish is a milligram figure against any plan, or who signs off on the step from one dose to the next.

  3. What the price includes

    The semaglutide injection is $185 a month and the tirzepatide injection is $295, and neither number appears on the card a reader lands on. Both sit behind a collapsed panel headed Pricing Details, while the card above it quotes the six-month rate. Three-month plans sit between the two, and the daily drops carry one plan at $145 with no ladder behind it, which means the drops and the six-month injection rung meet at the same figure from opposite directions.

  4. What it claims, and what it cites

    Both injections are compounded rather than manufactured, and the page states that compounded semaglutide is not FDA-approved and that the agency does not evaluate compounded products for safety, effectiveness or quality. A branded oral pill is sold alongside them. No compounding pharmacy is named anywhere on the site.

Where it holds up, and where it does not

  • Strength: The whole plan ladder is published, once the panel is opened
  • Strength: One price at every dose is stated across the site
  • Strength: A transferring patient keeps their current dose
  • Strength: Nothing is charged unless a prescription is written
  • Strength: Free two-day shipping is included
  • Limitation: Each injection card quotes the six-month rate as its headline
  • Limitation: The month-to-month figures sit inside a collapsed panel
  • Limitation: No compounding pharmacy is named
  • Limitation: No milligram dose is published against any plan

What the evidence says about this kind of treatment

The assessment above is about Näky. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader who opens the pricing panel before deciding what a headline rate means.
Wrong for
A buyer who wants the month-to-month figure on the first screen they see.

How Näky compares

SellerWho it suitsGo
SnagRxBuyers who want to stay month to month without paying much for itSee SnagRx
HealthRXBuyers who expect to escalate and want the later months pricedSee HealthRX
DreamHug MedicalReaders on the longest plan who want a wide coverage listSee DreamHug Medical
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: CurexCurveDadVantage Men's HealthDirect MedsDoctorAdamDrBrainRx

Sponsored alternative

Bodybuilding Health+

Readers who want to start without committing a year of money

Check Bodybuilding Health+ availability →

Frequently asked

Is $145 a month what a new semaglutide patient pays?
Only on the six-month plan. The one-month supply is $185, and the three-month plan sits between the two.
Do the drops have a multi-month discount?
No. The oral semaglutide drops are sold as a single one-month plan at $145, with no longer term offered.
Does the price rise as the dose goes up?
Näky states the same price applies at every dose, and repeats that promise in the bar running across every page.
Is Näky expensive compared with other GLP-1 telehealth sellers?
Näky publishes a starting figure of $145/mo. Across the 225 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $399 with a median of $179, which puts Näky below the median, toward the cheaper end. The other 18 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
Ruth AlvarezOutcomes writer · Reviewed and last verified September 2026

How this was assessed. The four questions above are answered from Näky’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.